Praxis Precision Medicines Inc. (PRAX)
NASDAQ: PRAX · Pharmaceutical Preparations · Boston, MA
Our rating: Cautious
Cautious reaffirmed at $337.59, moderate conviction, November 10, 2026.
Breaks if: The Cautious call would be wrong if, within six months of 10 November 2026, Praxis discloses a pivotal-trial primary endpoint hit with clear statistical significance and the stock holds above $420 for at least five consecutive sessions — indicating the market has concluded the core pipeline is intact and the 9 November event was a contained setback rather than a thesis-breaker. A sustained move through that level on a clinical catalyst would signal the valuation has found new fundamental footing.
Key figures
| Market value | $8.4B |
|---|---|
| Revenue, last 12 months | n/a |
| Net income, last 12 months | −$359M |
| Free cash flow, last 12 months | −$324M |
| Price to earnings | n/a |
| Free cash flow yield | −3.9% |
| Dividend yield | 0.0% |
| Operating margin | n/a |
| Return on equity | −44.8% |
| Beta to the S&P 500 | 1.01 |
| Volatility, annualized | 138.5% |
Reported quarters
| Quarter ending | Revenue | Year on year | Earnings per share | Free cash flow |
|---|---|---|---|---|
| September 30, 2026 | n/a | n/a | $-3.23 | −$83M |
| June 30, 2026 | n/a | n/a | $-2.87 | −$78M |
| March 31, 2026 | n/a | n/a | $-3.20 | −$86M |
| December 31, 2025 | $0.00 | −100.0% | $-3.51 | −$76M |
| September 30, 2025 | $0.00 | −100.0% | $-3.36 | −$65M |
| June 30, 2025 | $0.00 | −100.0% | $-3.31 | −$55M |
| March 31, 2025 | $0.00 | −100.0% | $-3.29 | −$53M |
| December 31, 2024 | $7M | 1349.1% | $-3.00 | −$56M |
Three-model forecasts for the next quarter
Written November 21, 2026, before the report. Each settles from the SEC filing.
- Diluted earnings per share are above zero: Claude 2%, Gemini 1%, Mistral 3%
- Free cash flow for the quarter is above zero: Claude 3%, Gemini 1%, Mistral 3%
20 ledger entries and 17 corporate events on record. Share price as of November 20, 2026. Research and education only. Not investment advice. Stoquity does not manage money or know your circumstances. Ratings, forecasts and lists are produced by software and AI models and can be wrong. Performance figures are hypothetical, measured on paper against a benchmark, and say nothing certain about the future.